Advanced treatments such as CAR-T cell therapy, gene therapy and newer immunotherapies are increasingly becoming available in India, creating a new challenge for health insurers. While the regulator has required coverage for several modern treatments since 2019, including robotic surgery, oral chemotherapy and immunotherapy, insurers often use sub-limits to manage their high and unpredictable costs. The challenge is particularly significant with CAR-T therapy, where treatment involves cell collection, laboratory engineering, conditioning chemotherapy, hospitalisation and follow-up care rather than a conventional hospital bill. Indigenous CAR-T therapies are reported to cost around ₹30 lakh–₹50 lakh, although associated diagnostics, hospitalisation and follow-up expenses can increase the overall financial burden.
The development is pushing the industry towards new health-insurance product design and clearer advanced-therapy coverage. A high sum insured alone may not provide adequate protection if an advanced-therapy clause imposes a much lower sub-limit or excludes the treatment. The article suggests dedicated cell- and gene-therapy benefits or modular riders, while also pointing to international experiments with outcome-based models involving insurers and drug manufacturers. For insurers, the challenge is to balance access with risk management because long-term evidence for some therapies remains limited and treatment costs can be substantial. Clear coverage of diagnostics, treatment and recovery stages could therefore become increasingly important as medical innovation moves faster than traditional insurance structures.
Want to deepen your expertise beyond today’s news?
Explore practical certification courses designed for banking, risk, insurance, compliance, ESG, AI, and emerging technologies professionals.
Learn from industry experts and earn certifications from RMAI and BFSI Sector Skill Council of India.
#Insurancenews

